1 recruiting, 1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Treatment-Related Acute Myeloid Leukemia: new trials by email Literature Review of Treatment-Related Acute Myeloid Leukemia trials Research Report on Treatment-Related Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML ALT-803 - High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2018-10-30 | 2018-11-09 |
Myelodysplastic Syndromes (2) · Leukemia, Biphenotypic, Acute (1) · Neoplasm Metastasis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Bone Marrow Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Disease Attributes (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
ALT-803 (1) · Azacitidine (1) · Cortisone (1) · Cytarabine (1) · Dexamethasone (1) · Dexrazoxane (1) · Doxorubicin (1) · Hydrocortisone (1) · Leucovorin (1) · Methotrexate (1) · Vincristine (1) · asparaginase erwinia chrysanthemi recombinant (1) · calaspargase pegol (1) · dexamethasone 21-phosphate (1) · dexamethasone acetate (1)
Andrew E. Place, MD (1) · Masonic Cancer Center, University of Minnesota (1)
United States (2)
Andrew E Place, MD, PhD (1) · Sarah Cooley, MD (1)